Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1148920110450030007
Nuclear Medicine and Molecular Imaging
2011 Volume.45 No. 3 p.7 ~ p.7
Evaluation of Salivary Gland Dysfunction Using Salivary Gland Scintigraphy in Sjogren¡¯s Syndrome Patients and in Thyroid Cancer Patients after Radioactive Iodine Therapy
Kang Ji-Yeon

Jang Su-Jin
Lee Won-Woo
Jang Sung-June
Lee Yun-Jong
Kim Sang-Eun
Abstract
Purpose: Salivary gland scintigraphy (SGS) provides an objective means of diagnosing salivary gland dysfunction in Sjogren¡¯s syndrome (SS) patients and in thyroid cancer patients after radioactive iodine (RAI) therapy. In the present study, SGS was performed in SS patients and in thyroid cancer patients post-RAI, and scintigraphic parameters were compared.

Methods: Twenty-eight SS patients (males:females?=?1:27, age 53.3?¡¾?11.9 years), 28 controls (males:females?=?3:25, age 54.1?¡¾?10.1 years), and 92 thyroid cancer patients (males:females?=?28:64, age 46.2?¡¾?12.9) who had undergone a session of high-dose RAI therapy (mean dose, 5.2?¡¾?1.5 GBq) were included. SGS was performed using Tc-99m pertechnetate (925 MBq). Scintigraphic parameters (parotid uptake ratio PU, submandibular uptake ratio SU, percentage parotid excretion %PE, and percentage submandibular excretion %SE) were measured and compared for SS, thyroid cancer post-RAI, and control patients.

Results: PU, SU, %SE, and %PE were all significantly lower in SS than in post-RAI thyroid cancer or control patients (p?
Conclusion: Scintigraphic parameters derived from SGS can play a crucial role in the detection of salivary gland dysfunction in SS patients and in post-RAI thyroid cancer patients.
KEYWORD
Salivary gland scintigraphy, Sjogren¡¯s syndrome, Radioactive iodine therapy, Thyroid cancer, Tc-99m pertechnetate
FullTexts / Linksout information
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø